Articles From: Alder BioPharmaceuticals Added to Russell 3000(R) Index to EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union


BOTHELL, Wash., June 27, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc., ("Alder") (Nasdaq:ALDR) , a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced that Alder will be added to the Russell 3000® Index at the close of the market today, Friday, June 27, 2014 when Russell Investments reconstitutes its set of U.S. and global equity indexes.
Sign-up for Alder BioPharmaceuticals Added to Russell 3000(R) Index investment picks
BEIJING, June 27, 2014 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. ("iKang" or the "Company") (Nasdaq:KANG) , the largest provider in China's fast growing private preventive healthcare services market in terms of revenue in 2013, announced today it will attend the Citi Healthcare Corporate Day 2014 to be held on July 8 th at Island Shangri-la Hotel, Pacific Place, Supreme Court Road, Central, Hong Kong.
Sign-up for iKang to Attend Citi Healthcare Corporate Day 2014 in Hong Kong investment picks
Zep Inc. (NYSE:ZEP) , a leading consumable chemical packaged goods company that manufactures a wide variety of high-performance maintenance and cleaning chemicals, is pleased to announce that at its meeting yesterday, the Board of Directors declared a quarterly cash dividend of $0.05 cents per common share.
Sign-up for Zep Inc. Declares Quarterly Dividend investment picks
MSCI Inc. (NYSE:MSCI) announced today that it has agreed to acquire GMI Ratings, a provider of ESG (environmental, social and governance) ratings and research to institutional investors, through its subsidiary MSCI ESG Research Inc. The transaction is expected to close in the third quarter, subject to customary closing conditions.
Sign-up for MSCI to Acquire GMI Ratings investment picks
API Technologies Corp.
Sign-up for API Technologies Announces Second Quarter Earnings Call investment picks
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company developing nucleotide therapeutics for patients with cancer and orphan diseases, today announced that it will be added to the Russell 3000® and Russell 2000® Indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on Friday, June 27, 2014, according to a preliminary list of additions posted on June 13, 2014 on www.russell.com/indexes .
Sign-up for Idera Pharmaceuticals to be Added to the Russell 3000® and Russell 2000® Indexes investment picks
D.R. Horton, Inc. (NYSE:DHI), America’s Builder, announced today that the Company will release financial results for its third quarter ended June 30, 2014 on Thursday, July 24, 2014 before the market opens.
Sign-up for D.R. Horton, Inc., America’s Builder, to Release 2014 Third Quarter Earnings on July 24, 2014 investment picks
2014/6/27
Leiden, The Netherlands, June 27, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) , the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that Dr.
Sign-up for Prosensa Awarded $200,000 Research Grant from PPMD investment picks
The only connectivity solutions company to win the prestigious award from EDN SHANGHAI , June 27, 2014 /PRNewswire/ -- TE Connectivity Ltd.
Sign-up for TE Connectivity Wins "Strongest Sustainable Development" Award In China investment picks
First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and RIDGEFIELD, Conn., June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes.
Sign-up for CHMP Recommends Lilly and Boehringer Ingelheim's Investigational New Insulin Glargine Product for Approval in the European Union investment picks
First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and INGELHEIM, Germany , June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes.
Sign-up for CHMP Recommends Lilly and Boehringer Ingelheim's New Insulin Glargine Product for Approval in the European Union investment picks
FUZHOU, China , June 27, 2014 /PRNewswire/ -- Pingtan Marine Enterprise Ltd.
Sign-up for Pingtan Marine Enterprise Ltd. Engages BDO China to Audit its Corporate Subsidiaries investment picks
2014/6/27
http://media.marketwire.com/attachments/201403/230586_GARB3-10-14UpdatedLogo.JPG http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1127372&ProfileId=051205&sourceType=1 LARGO, FL --
Sign-up for Garb Oil & Power Corporation Announces Postponement of Reverse Split investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0954565001&sourceType=1 http://www.ccnmatthews.com/logos/20081103-he100.jpg LONDON, UNITED KINGDOM --
Sign-up for Heritage Oil Plc: Sanction of Scheme investment picks
BUFFALO, N.Y., June 27, 2014 (GLOBE NEWSWIRE) -- Synacor Inc. (Nasdaq:SYNC) today issued the following response to an open letter to its Board of Directors received from two of its stockholders: Synacor values the views and enthusiasm of its stockholders and welcomes constructive input toward our shared goal of maximizing long-term value for all stockholders.
Sign-up for Synacor Responds to Stockholder Letter investment picks
NEW YORK , June 27, 2014 /PRNewswire/ -- MFC Industrial Ltd.
Sign-up for MFC Industrial Announces New CFO Appointment investment picks
EMC Metals Corp.
Sign-up for EMC Announces Completion of C$885,308 First Tranche Private Placement investment picks
Acacia Research Corporation (NASDAQ: ACTG) announced today that its Online News Link LLC subsidiary has entered into a settlement and patent license agreement with Wayfair LLC.
Sign-up for Acacia Subsidiary Enters into Settlement and Patent License Agreement with Wayfair LLC investment picks
2014/6/27
- Revenues and Gross Margins Increase Strongly - Conference Call to Discuss Results at 8:00 a.m. EDT on June 27, 2014 Dial-in Numbers Below BEIJING , June 27, 2014 /PRNewswire/ -- Lentuo International Inc. (NYSE: LAS) ("Lentuo" or the "Company"), a leading non-state-owned automobile retailer headquartered in Beijing , today reported its financial results for the first quarter ended March 31, 2014 .
Sign-up for Lentuo International Reports First Quarter 2014 Financial Results with Net Income of US$1.5 Million investment picks
2014/6/27
Orbotech Ltd.
Sign-up for Orbotech Reaches Agreement with Ion investment picks
2014/6/27
By Jeffry Bartash, MarketWatch Thanks for nothing, Supreme Court -- there's no other simple or cheap way to watch network television stations on a mobile phone or tablet now that the highest court in the land ruled Aereo infringed copyright law.
Sign-up for UPDATE: You can build your own Aereo -- at a cost investment picks
BLAINE, Wash., June 27, 2014 (GLOBE NEWSWIRE) -- Mobetize Corp.
Sign-up for Mobetize Closes a Private Equity Placement Issuing 1,122,831 Investment Units for Gross Proceeds of $842,125 investment picks
EMCOR Group, Inc. (NYSE: EME), a Fortune 500 ® leader in mechanical and electrical construction, industrial and energy infrastructure, and building services for a diverse range of businesses announced that its subsidiary EMCOR Government Services (EGS) has been awarded contracts for operation, maintenance, and repair of systems and services with an expanded scope of work at Fort Belvoir Community Hospital and the building housing the Northern Region Medical Command in Fort Belvoir, Virginia.
Sign-up for EMCOR Group, Inc. Subsidiary Awarded Contract for Operations and Maintenance at Fort Belvoir Community Hospital and the Northern Region Medical Command investment picks
2014/6/27
5 Questions Newport Private Wealth Clients Should Ask Their Financial Advisors about the Tuckamore Capital Management Buyout Canada NewsWire Instruct Your Financial Advisors to Vote NO to the Tuckamore MBO Go to www.voteNOtuckamoreMBO.com to learn more TORONTO , June 27, 2014 /CNW/ - Access Holdings Management Company LLC ("Access Holdings" or "we") urges clients of Newport Private Wealth Inc. ("Newport") which own common shares of Tuckamore Capital Management Inc. (the "Company" or "Tuckamore") (TSX: TX) to instruct their Newport financial advisor to vote NO to the Tuckamore MBO at a Special Meeting of Shareholders to be held on July 15 th , 2014.
Sign-up for 5 Questions Newport Private Wealth Clients Should Ask Their Financial Advisors about the Tuckamore Capital Management Buyout investment picks
ZHUHAI, China and CAMBRIDGE, England , June 27, 2014 /PRNewswire/ -- Actions Semiconductor Co., Ltd.
Sign-up for Actions Semiconductor Licenses ARM Cortex-A50 Processor Family to Target 64-bit Tablet Market investment picks
Starwood Waypoint Residential Trust (NYSE:SWAY) (“the Company”), a leading single-family rental real estate investment trust (“REIT”), announced today that it completed a $117.0 million purchase of 1,441 non-performing loans (“NPLs”). The purchase price represents approximately 61.8% of the total unpaid principal balance (“UPB”) of $189.4 million and 68.2% of the estimated broker price opinion (“BPO”) value of $171.6 million.
Sign-up for Starwood Waypoint Residential Trust Acquires Large Pool of Non-Performing Loans investment picks
2014/6/27
CRANBURY, N.J. , June 27, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it is joining the Russell Microcap® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes later today.
Sign-up for Palatin Technologies to Join Russell Microcap Index investment picks
2014/6/27
By David Enrich, Noemie Bisserbe and Andrew R.
Sign-up for BNP plans to slash dividend over U.S. settlement investment picks
2014/6/27
Would Change Vote For Credible Higher-Valued Alternative Voting Against Management "Golden Parachute" Plan MILL VALLEY, Calif.
Sign-up for Lawndale Capital Mgmt To Conditionally Vote For Equal Energy Sale investment picks
TARRYTOWN, N.Y. , June 27, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA ® (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of visual impairment due to diabetic macular edema (DME). The decision of the European Commission is expected in the second half of 2014.
Sign-up for EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Alder BioPharmaceuticals Added to Russell 3000(R) Index to EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices